WO2004096169A1 - Preparation dermatologique - Google Patents

Preparation dermatologique Download PDF

Info

Publication number
WO2004096169A1
WO2004096169A1 PCT/IT2004/000158 IT2004000158W WO2004096169A1 WO 2004096169 A1 WO2004096169 A1 WO 2004096169A1 IT 2004000158 W IT2004000158 W IT 2004000158W WO 2004096169 A1 WO2004096169 A1 WO 2004096169A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
oil
topical use
alpha
brij
Prior art date
Application number
PCT/IT2004/000158
Other languages
English (en)
Inventor
Siro Passi
Ornella De Pita'
Original Assignee
Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione - Istituto Dermopatico Dell'immacolata
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione - Istituto Dermopatico Dell'immacolata filed Critical Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione - Istituto Dermopatico Dell'immacolata
Publication of WO2004096169A1 publication Critical patent/WO2004096169A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Definitions

  • This invention relates to the dermatological field, and more particularly to the realization of formulations for topical administrations whose aim is the cutaneous protection and prevention against oxidation exogenous and endogenous damages, both by re-establishing equilibrium of lipids and of sebaceous and epidermal anti-oxidants which are essential for cutaneous homeostasis and become altered by oxidative stress, and by the presence of molecules endowed with specific lenitive and anti-inflammatory activity.
  • the presence of molecules is provided which are both chelating agents for transition metals and capable of reactivating the superficial circulation.
  • Main characteristics of such formulations are the following ones: a) they are endowed with activity at cutaneous level as anti-oxidants and scavengers, as chelating agents of transition metals and have lenitive and anti-inflammatory properties; b) they reduce the occurrence of contact dermatitises and counteract the same; c) they are capable of inducing the increase in cutaneous ceramides; d) they have a lipidic composition that from the qualitative and quantitative standpoint reflects as much as possible human sebum; e) they show the same anti-oxidants as those found in sebum and epidermis; f) they are capable of inhibiting histidine decarboxylation and hence histamine formation; g) they have a remarkable hydrating action for skin; h) they have molecules which are capable of acting on the superficial circulation by protecting and reactivating the same; i) they have molecules featuring anti-UV-A and anti-UV-B activity.
  • the dermatological formulations according to the present finding satisfy the following main requisites: a) they contain flavonoids and polyphenols of natural origin which are extremely active at the cutaneous level both as antioxidants and scavengers, and as chelating agents of transition metals, and moreover they all are endowed with anti-inflammatory and lenitive properties; b) they contain molecules which are capable of chelating and removing the transition metals which are of importance in contact dermatitises; c) they contain vitamin PP (nicotinamide) involved in the increase of cutaneous ceramides; d) they contain molecules which are deputed exclusively to cutaneous hydration; e) they have a lipidic composition similar to human sebum; f) they contain a set of lipophilic antioxidants analgous to those observed in sebum and in epidermis (S.
  • formulations mentioned above, described in the previous patent applications have a merely biocosmetic objective, which is essentially addressed at restoration of lipidic fractions and of cutaneous and epidermic antioxidants which have been impaired by the endogenous and exogenous oxidative stress, in particular during ageing. Stated otherwise, they are biocosmetic formulations that can be employed for preventing and treating any cutaneous unaesthetical defects which are due to ageing.
  • Said improvement has been obtained by providing natural molecules like the following ones: flavonoids and polyphenols, within their natural matrix annd extremely active at the cutaneous level like those present in plant extracts ( illowherb, Ginkgo biloba, Rosmarinus officinalis, Hamamelis virginiana, Matricaria, Boswellia serrata, Olive tree) which are well known because of their anti- inflammatory action, generally ascribed to the high concentrations in the extracts of the molecules mentioned above which are capable of acting as scavengers for the reactive species of oxygen and of nitrogen, of other radicals and inflammatory cytokines .
  • Said anti-inflammatory efficiency is further made more powerful by the joint presence of natural antioxidants (d-RRR-alfa-tocopherol, ubiquinone and stabilized vitamin C) in the creams
  • chelating agents of transition metals and of heavy metals as for instance phytic acid, which are present in wheat and other cereals.
  • Transition metals- are the main responsible agents for contact dermatitis
  • phytic acid is synergized in its activity by the joint presence of disodium EDTA, flavonoids and polyphenols, these compounds being also endowed with chelating action escin and buphenine, that play an important role in microcirculation: the first one, strengthened in a meaningful way by flavonoids and by vitamin C, is usually employed in the treatment of symptoms connected with peripheral incompetence of venous and lymphatic vessels, the second one is a peripheral vasodilator which develops a direct action on capillary arterioles and on arteries.
  • flavonoids and polyphenols recourse have been made preferably to the total extracts of:
  • Matricariae flos (containing apigenin and other flavonoids, alfa-bisabolol, azulene) in the amount of 0,3 - 1,0% by weight
  • Rosmarinus officinalis (containing carnosol , carnosinic acid, rosmarinic acid, ursolic acid) in the amount of 0,3 - 1,0% by weight
  • Hamamelis virginiana containing polyphenols, gallotannin, hamamelotannins, etc.
  • the extract of Boswellia serrata containing boswellic acids
  • oleuropein standardized extract of olive tree leaves
  • green tea extract rich in catechins, epigallocatechins and other polyphenols
  • extract of Ginkgo biloba rich in flavonoids, biflavonoids, proanthocyanidins , ginkgolides, etc.
  • Willowherb extract containing ellagic acid, in addition to quercetin and kaempferol and other flavonoids
  • Vitamin PP in the amount of 0,2-0,5% by weight is employed as it is involved in the increase in cutaneous ceramides which show to be decreased both in senile skin and in skin suffering from atopic dermatitis. Moreover, topical administration of vitamin PP lowers the TEWL (transcutaneous water loss) of dry skin (Tanno, O., Ota, Y. , Kitamura, M. Et al . , 2000, Br. J. Dermatol . , 143 (3) :524-531) .
  • TEWL transcutaneous water loss
  • Glycerol in the amount of 2-3% by weight, zinc PCA in the amount of 0,5-5% by weight and mannitol in the amount of 0,5-1% by weight are three molecules deputed exclusively to cutaneous hydration; moreover, mannitol is also a powerful scavenger of the hydroxyl radical that, as is well known, is the most reactive, toxic, oxidant and mutagenic species existing in nature (point d) .
  • escin and bufenine play an important role in microcirculation: the first one, meaningfully strengthened by flavonoids and by vitamin C, is usually employed in treating symptoms connected with peripheral incompetence of venous and lymphatic vessels, the second one is a peripheral vasodilator that develops a direct action on capillary arterioles and on arteries (point h) . It is a further feature of the present finding in some cases that of providing the employment of benzophenon- 3, in the amount of 2% by weight, as a well-known anti-UV-A and anti-UV-B sun filter activity, or the employment of the most recent Tinosorb M which has the same characteristics (point i) .
  • HAZELNUT OIL or olive or Macadamia oil
  • BRIJ-72 steareth 21
  • CETYL STEARYL ALCOHOL 2.5 2.0-4.0 HAMAMELIS (extract) 2 1..5-3..0
  • MANNITOL 1 0. .5-1. .5
  • SILICONE OIL 350 0.5 0, .3-1, .0
  • CARBOPOL ETD 2020 0.5 0. .4-1, .0
  • HAZELNUT OIL or Olive oil or Macada ia- oil
  • BRIJ-72 steareth 2
  • BENZOPHENON-3 2.0-4.0 or TINOSORB-M 3
  • CETYL STEARYL ALCOHOL 2.5 2.0-3.5
  • HAMAMELIS extract
  • Jojoba oil, "sonora” type 5 3.0-6.0 FINSOLV TN (C12-C15 alkyl- benzoate) 5 HAZELNUT OIL (or Olive oil or Macadamia oil) 7.5 3.0-8.0
  • SILICONE OIL 350 0.5 0.3-1.0 DISODIUM EDTA 0.4
  • HAZELNUT OIL or Olive oil or Macadamia oil 3 2.0-6.0
  • AVOCADO OIL 1 1.0-3.0 BRIJ-721 3 1.5-3.5
  • VENOCIN (90% Escin) 0.5 0.3-1.0
  • GLYCOL SALICYLATE 1 0.5-2.0
  • Montanov 68 (cetostearyl- glucoside, cetearyl alcohol) 2.5 2-3.5 jojoba oil 2 1.5-3.0 Hazelnut oil 2 1.5-3.0
  • Glycerin 2 2.0-4.0
  • Simulsol 165 PEG 100 stearate, glyceryl stearate 0.75

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une préparation dermatologique contenant des principes actifs qui sont exclusivement d'origine naturelle, ladite préparation étant destinée à protéger la peau et à prévenir les atteintes oxydatives exogènes et endogènes, à la fois par rétablissement de l'équilibre des lipides sébacés et épidermiques et des antioxydants indispensable à l'homéostasie cutanée, et qui est altéré par le stress oxydatif, et par la présence d'un groupe de molécules possédant une activité lénitive et anti-inflammatoire spécifique. L'adjonction complémentaire de molécules comprenant des chélates de métaux de transition et permettent additionnellement de réactiver la circulation superficielle, est également décrite.
PCT/IT2004/000158 2003-04-29 2004-03-29 Preparation dermatologique WO2004096169A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2003A000204 2003-04-29
IT000204A ITRM20030204A1 (it) 2003-04-29 2003-04-29 Formulazione dermatologica.

Publications (1)

Publication Number Publication Date
WO2004096169A1 true WO2004096169A1 (fr) 2004-11-11

Family

ID=29765787

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2004/000158 WO2004096169A1 (fr) 2003-04-29 2004-03-29 Preparation dermatologique

Country Status (2)

Country Link
IT (1) ITRM20030204A1 (fr)
WO (1) WO2004096169A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063422A1 (fr) * 2004-12-16 2006-06-22 Anidro Do Brasil Extrações Ltda Formule pour application locale basée sur des extraits de camomille, de fruits de la passion et d'artichaut
FR2885301A1 (fr) * 2005-03-17 2006-11-10 Jean Noel Thorel Composition cosmetique ou dermatologique destinee a diminuer et/ou corriger les rougeurs de la peau
GB2451224A (en) * 2007-05-09 2009-01-28 Frances Prenna Jones Cosmetic composition comprising an exfoliant, astringent, antioxidant and moisturiser
FR2924023A1 (fr) * 2007-11-28 2009-05-29 Biolog Vegetale Yves Rocher Sa Utilisation d'un extrait d'aloe pour la promotion et le renfort de la cohesion des cellules de la peau
ITMI20110202A1 (it) * 2011-02-11 2012-08-12 Cristina Chillemi Composizione e metodo per rendere una ceretta indolore.
WO2013093947A1 (fr) * 2011-12-21 2013-06-27 Motolese Pasquale Composition cosmétique et ses utilisations dans le traitement de lipodystrophies
EP2404641A3 (fr) * 2009-08-28 2014-06-11 ROVI Cosmetics International GmbH Formule cosmétique pour la réduction de l'apparence extérieure de la cellulite ou de la peau d'orange
JP2014527990A (ja) * 2011-09-30 2014-10-23 アルナファルム ゲーエムベーハー ウント コンパニー カーゲーＡｌｎａｐｈａｒｍ ＧｍｂＨ ＆ Ｃｏ． ＫＧ 皮膚に塗布する組成物、およびその使用
EP2829264A4 (fr) * 2012-03-22 2015-09-09 Fujifilm Corp Composition d'émulsion hautement transparente et cosmétique hautement transparent
FR3030273A1 (fr) * 2014-12-23 2016-06-24 Laboratoires Lea Composition comprenant un extrait de lotus, un extrait d'hamamelis et du zinc, et son utilisation cosmetique
ITUB20153171A1 (it) * 2015-08-20 2017-02-20 Aboca Spa Societa Agricola Composizione comprendente tannini
US9775908B2 (en) 2007-07-10 2017-10-03 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Pharmaceutical preparations containing highly volatile silicones
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
CN109164190A (zh) * 2018-10-16 2019-01-08 云南清莲生物科技有限公司 一种区分不同产地红茶的方法
EP3471696A4 (fr) * 2016-06-20 2020-03-11 Essity Hygiene And Health Aktiebolag Composition désinfectante pour les mains
CN111249195A (zh) * 2020-02-28 2020-06-09 广州艾蓓生物科技有限公司 一种清爽收敛水及其制备方法
CN111616975A (zh) * 2020-06-19 2020-09-04 广州熙然化妆品有限公司 一种祛痘组合物及其制备方法
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
CN115444773A (zh) * 2022-08-23 2022-12-09 陕西畅想制药有限公司 含乙二醇水杨酸酯的抗炎修护组合物及制备方法和应用
CN115670952A (zh) * 2022-11-11 2023-02-03 深圳八零赞电子商务有限公司 一种控油抗痘的组合物、护肤品及制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784847A (en) * 1987-04-28 1988-11-15 Zulliger Bopp Monika G Wine-containing skin-care products
FR2699818A1 (fr) * 1992-12-24 1994-07-01 Oreal Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko.
JP2001302438A (ja) * 2000-04-25 2001-10-31 Noevir Co Ltd 皮膚外用剤
JP2001354537A (ja) * 2000-06-08 2001-12-25 Noevir Co Ltd 皮膚外用剤
WO2002026207A2 (fr) * 2000-09-28 2002-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione - Istituto Dermopatico Dell'immacolata Formulation cosmetique
WO2002043691A1 (fr) * 2000-11-29 2002-06-06 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione - Istituto Dermopatico Dell'immacolata Creme pour la peau stimulant la circulation sanguine superficielle
WO2003015738A1 (fr) * 2001-08-18 2003-02-27 Cognis Iberia, S.L. Melanges de principes actifs

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784847A (en) * 1987-04-28 1988-11-15 Zulliger Bopp Monika G Wine-containing skin-care products
FR2699818A1 (fr) * 1992-12-24 1994-07-01 Oreal Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko.
JP2001302438A (ja) * 2000-04-25 2001-10-31 Noevir Co Ltd 皮膚外用剤
JP2001354537A (ja) * 2000-06-08 2001-12-25 Noevir Co Ltd 皮膚外用剤
WO2002026207A2 (fr) * 2000-09-28 2002-04-04 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione - Istituto Dermopatico Dell'immacolata Formulation cosmetique
WO2002043691A1 (fr) * 2000-11-29 2002-06-06 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione - Istituto Dermopatico Dell'immacolata Creme pour la peau stimulant la circulation sanguine superficielle
WO2003015738A1 (fr) * 2001-08-18 2003-02-27 Cognis Iberia, S.L. Melanges de principes actifs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200218, Derwent World Patents Index; Class D21, AN 2002-134657, XP002292764 *
DATABASE WPI Section Ch Week 200232, Derwent World Patents Index; Class B04, AN 2002-274914, XP002292763 *
PASSI S. ET AL.: "invecchiamento cutaneo e sua prevenzione", PROGRESS IN NUTRITION, vol. 3, no. 4, 2001, ITALY, pages 13 - 24, XP002292453 *
photocopy of the corresponding commercial packaging *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063422A1 (fr) * 2004-12-16 2006-06-22 Anidro Do Brasil Extrações Ltda Formule pour application locale basée sur des extraits de camomille, de fruits de la passion et d'artichaut
FR2885301A1 (fr) * 2005-03-17 2006-11-10 Jean Noel Thorel Composition cosmetique ou dermatologique destinee a diminuer et/ou corriger les rougeurs de la peau
GB2451224A (en) * 2007-05-09 2009-01-28 Frances Prenna Jones Cosmetic composition comprising an exfoliant, astringent, antioxidant and moisturiser
US9775908B2 (en) 2007-07-10 2017-10-03 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Pharmaceutical preparations containing highly volatile silicones
FR2924023A1 (fr) * 2007-11-28 2009-05-29 Biolog Vegetale Yves Rocher Sa Utilisation d'un extrait d'aloe pour la promotion et le renfort de la cohesion des cellules de la peau
EP2404641A3 (fr) * 2009-08-28 2014-06-11 ROVI Cosmetics International GmbH Formule cosmétique pour la réduction de l'apparence extérieure de la cellulite ou de la peau d'orange
ITMI20110202A1 (it) * 2011-02-11 2012-08-12 Cristina Chillemi Composizione e metodo per rendere una ceretta indolore.
JP2014527990A (ja) * 2011-09-30 2014-10-23 アルナファルム ゲーエムベーハー ウント コンパニー カーゲーＡｌｎａｐｈａｒｍ ＧｍｂＨ ＆ Ｃｏ． ＫＧ 皮膚に塗布する組成物、およびその使用
WO2013093947A1 (fr) * 2011-12-21 2013-06-27 Motolese Pasquale Composition cosmétique et ses utilisations dans le traitement de lipodystrophies
EP2829264A4 (fr) * 2012-03-22 2015-09-09 Fujifilm Corp Composition d'émulsion hautement transparente et cosmétique hautement transparent
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
FR3030273A1 (fr) * 2014-12-23 2016-06-24 Laboratoires Lea Composition comprenant un extrait de lotus, un extrait d'hamamelis et du zinc, et son utilisation cosmetique
ITUB20153171A1 (it) * 2015-08-20 2017-02-20 Aboca Spa Societa Agricola Composizione comprendente tannini
CN108136210A (zh) * 2015-08-20 2018-06-08 阿波卡-阿格里科拉共同股份公司 含有单宁的组合物
AU2016307998B2 (en) * 2015-08-20 2019-02-21 Aboca S.P.A Società Agricola Composition comprising tannins
US11357813B2 (en) 2015-08-20 2022-06-14 Aboca S.P.A. Società Agricola Composition comprising tannins
WO2017029643A1 (fr) * 2015-08-20 2017-02-23 Aboca S.P.A Società Agricola Composition contenant des tanins
EA039055B1 (ru) * 2015-08-20 2021-11-26 Абока С.П.А. Сосиета' Агрикола Композиция, содержащая танины
EP3471696A4 (fr) * 2016-06-20 2020-03-11 Essity Hygiene And Health Aktiebolag Composition désinfectante pour les mains
CN109164190A (zh) * 2018-10-16 2019-01-08 云南清莲生物科技有限公司 一种区分不同产地红茶的方法
CN111249195B (zh) * 2020-02-28 2022-06-07 广州艾蓓生物科技有限公司 一种清爽收敛水及其制备方法
CN111249195A (zh) * 2020-02-28 2020-06-09 广州艾蓓生物科技有限公司 一种清爽收敛水及其制备方法
CN111616975B (zh) * 2020-06-19 2020-11-20 广州熙然化妆品有限公司 一种祛痘组合物及其制备方法
CN111616975A (zh) * 2020-06-19 2020-09-04 广州熙然化妆品有限公司 一种祛痘组合物及其制备方法
CN115444773A (zh) * 2022-08-23 2022-12-09 陕西畅想制药有限公司 含乙二醇水杨酸酯的抗炎修护组合物及制备方法和应用
CN115444773B (zh) * 2022-08-23 2023-09-05 陕西畅想制药有限公司 含乙二醇水杨酸酯的抗炎修护组合物及制备方法和应用
CN115670952A (zh) * 2022-11-11 2023-02-03 深圳八零赞电子商务有限公司 一种控油抗痘的组合物、护肤品及制备方法
CN115670952B (zh) * 2022-11-11 2024-03-19 深圳八零赞电子商务有限公司 一种控油抗痘的组合物、护肤品及制备方法

Also Published As

Publication number Publication date
ITRM20030204A0 (it) 2003-04-29
ITRM20030204A1 (it) 2004-10-30

Similar Documents

Publication Publication Date Title
WO2004096169A1 (fr) Preparation dermatologique
US8435541B2 (en) Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
US6572868B1 (en) Restructuring complex for cosmetic compositions
AU2007281372B2 (en) Anti-aging compositions comprising Menyanthes trifoliata leaf extracts and methods of use thereof
US20130195925A1 (en) Anti aging application and method for treating aging
US20040013618A1 (en) Cosmetic formulation
KR20190122269A (ko) 식물 추출물을 포함하는 국소 스킨 케어 제형
WO2008139182A2 (fr) Composition pour le soin de la peau
US20040241197A1 (en) Cosmetic or dermatological preparations including creatinine or a derivative thereof and creatine or a derivative thereof and methods of applying the preparations to the skin
CA2447525C (fr) Compositions pharmaceutiques et cosmetiques empechant le vieillissement de la peau
CA2471657C (fr) Procedes d'amelioration de l'aspect esthetique de la peau
AU2002342279A1 (en) Pharmaceutical and cosmetic compositions against skin aging
KR102323714B1 (ko) 화장료 피부관리 조성물
EP1414401A1 (fr) Utilisation de creatinine et/ou de derives de la creatinine dans des preparations cosmetiques ou dermatologiques
US20030108510A1 (en) Skin cream stimulating the surface bloodstream
RU2671511C1 (ru) Косметическая композиция для ухода за волосами и кожей головы (варианты)
KR102475898B1 (ko) 그라비올라 항균 추출물을 함유하는 화장료 조성물 및 그 제조방법
CN113116767B (zh) 醒肤露及其制备方法和胶原酶抑制剂
RU2666602C1 (ru) Косметический крем для ухода за кожей
KR100894581B1 (ko) 태양 복사로 야기되는 손상으로부터 피부를 보호하기위한약제와 화장품 조성물
KR101457972B1 (ko) 노화방지용 화장료 조성물
FR3067593A1 (fr) Utilisation d'extraits de plantes pour le traitement dermatocosmetique des etats inflammatoires lies a une surproduction de il-17
KR102571999B1 (ko) 피부 활력 증진 및 피부 트러블 개선용 화장료 조성물
JP7225372B2 (ja) 皮膚の老化の兆候に有効であるホワイトファーの木の枝の精油の使用
KR20230095381A (ko) 다래열매추출물, 다래꽃추출물 및 다래줄기추출물을 포함하는 화장료조성물 및 그 제조방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase